Physician profile
Deepak N Kapadia
NPI 1023065745
$5,793.66
in general payments reported to CMS, 2019-2025
29 companies · $489 in 2025
The $489 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,120 · 2020: $618 · 2021: $1,222 · 2022: $965 · 2023: $720 · 2024: $659 · 2025: $489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,868.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,041.31 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $683.39 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $636.38 | 2019-2025 | Eliquis, Camzyos |
| Abbott Laboratories | $554.99 | 2019-2024 | Cardiomems, Aveir |
| Pfizer INC. | $478.64 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $326.09 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.86 | 2019-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $248.67 | 2020-2025 | |
| Amgen INC. | $211.94 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $197.63 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $176.78 | 2019-2024 | Farxiga |
| Amarin Pharma, INC. | $164.62 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.04 | 2021-2025 | |
| Elutia, INC. | $104.87 | 2021-2023 | |
| Lundbeck LLC | $98.73 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $84.57 | 2022-2024 | Bodyguardian |
| Kowa Pharmaceuticals America, INC. | $52.98 | 2019-2022 | |
| Cvrx, INC. | $48.09 | 2024 | Barostim Neo System |
| Glaxosmithkline, LLC. | $44.27 | 2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $32.66 | 2024-2025 | Nexletol |
| Edwards Lifesciences Corporation | $28.69 | 2025 | Sapien 3 Ultra Resilia |
| Preventice Services, LLC | $28.02 | 2021 | |
| Alnylam Pharmaceuticals INC. | $26.71 | 2024 | Onpattro |
| Allergan, INC. | $23.21 | 2019 | |
| Scpharmaceuticals INC. | $22.65 | 2025 | |
| Novo Nordisk INC | $14.92 | 2021 | |
| Terumo Medical Corporation | $13.80 | 2021 | |
| Inspire Medical Systems, INC. | $13.14 | 2023 | Inspire |
| Bardy Diagnostics, INC. | $13.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Kapadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.